Arena Pharmaceuticals, Inc. (ARNA) |
|
99.99 0 (0%)
|
12-31 19:00 |
|
Open: |
99.97 |
Pre. Close: |
99.99 |
|
High:
|
100 |
Low:
|
99.97 |
|
Volume:
|
0 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2022-11-18 4:18:42 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 116.79 One year: 136.42 |
| Support: |
Support1: 99.98 Support2: 99.97 |
| Resistance: |
Resistance1: 100 Resistance2: 116.79 |
| Pivot: |
99.98 |
| Moving Average: |
MA(5): 99.98 MA(20): 99.98
MA(100): 99.98 MA(250): 96.02  |
| MACD: |
MACD(12,26): 0  Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 66.6 %D(3): 66.6 |
| RSI: |
RSI(14): 78.9 |
| 52-week: |
High: 100 Low: 48.11 |
| Average Vol(K): |
3-Month: 0 (K) 10-Days: 0 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ARNA ] has closed Bollinger Bands are 0% narrower than normal. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
100.09 - 100.58 |
100.58 - 101 |
|
Low:
|
98.78 - 99.36 |
99.36 - 99.85 |
|
Close:
|
99.14 - 100.02 |
100.02 - 100.78 |
|
Company Description |
|
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc. |
Headline News |
Mon, 14 Mar 2022
Pfizer concludes Arena Pharmaceuticals acquisition for $6.7bn - Pharmaceutical Technology
Fri, 11 Mar 2022
Pfizer Completes Acquisition of Arena Pharmaceuticals - Pfizer
Tue, 08 Mar 2022
Arena Pharma stock ticks higher on Nasdaq delisting notice for ... - Seeking Alpha
Wed, 23 Feb 2022
Arena Reports Fourth Quarter and Full Year 2021 Financial Results ... - Business Wire
Tue, 21 Dec 2021
Pfizer Acquires Arena At A 100% Premium (NASDAQ:ARNA) - Seeking Alpha
Wed, 15 Dec 2021
Corporate Compliance - Pfizer
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
-248 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
6.166e+007 (%) |
|
% Held by Institutions
|
6.152e+007 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-4.1945e+008 |
|
EPS Est Next Qtl
|
-0.67 |
|
EPS Est This Year
|
-2.95 |
|
EPS Est Next Year
|
-2.74 |
|
Book Value (p.s.)
|
-10.15 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
10 |
|
Return on Equity (ttm)
|
483.2 |
|
Qtrly Rev. Growth
|
-70.4 |
|
Gross Profit (p.s.)
|
-5.26 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-8.65 |
|
Qtrly Earnings Growth
|
-5.4179e+008 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-9.87 |
|
Price to Sales
|
166362 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
6.02e+006 |
|
Forward Dividend
|
5.11e+006 |
|
Dividend Yield
|
6020600% |
|
Dividend Pay Date
|
2017-06-18 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
